Pipeline and New Business WinsLifecore said it has 11 development programs that could potentially commercialize by the end of 2028. Since the end of the quarter, Lifecore also closed a late-stage injectable program with a specialty biopharmaceutical company. Lifecore maintained its 2026 guidance for revenue of $120 million to $125 million and adjusted EBITDA of $20.5 million to $25 million. Lifecore ended the quarter with approximately $38.8 million in liquidity, including $17.2 million of cash and $21.6 million of revolving credit availability. About Lifecore Biomedical (NASDAQ:LFCR)Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota.